$SPRO News

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Spero Therapeutics Files Prospectus To Offer Up To $300M In Securities

Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript

Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary

Spero Therapeutics Q2 Earnings Call Highlights

Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Innovent licenses IBI355 rights to Spero for up to $1.1bn

Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing

Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO)